OSI shares jump on lung cancer study data
S hares of OSI Pharmaceuticals Inc. jumped Friday after the biotechnology company and its partner Genentech Inc. said their drug Tarceva met its main goal in a study of stemming the spread of lung...
View ArticleOSI shares fall Tarceva study concern
Shares of OSI Pharmaceuticals Inc. fell Friday as Wall Street expressed disappointment over otherwise positive late-stage study results for Tarceva as an initial treatment for lung cancer. The stock...
View ArticleOSI shares rise on positive Tarceva study data
Shares of OSI Pharmaceuticals Inc. jumped Monday after the company and its partner Roche said Tarceva met a key secondary goal of a late-stage study by improving the overall survival rate of lung...
View ArticleTokyo firm renews OSI bid
A Japanese pharmaceuticals company is buying time when it comes to its efforts to buy Melville-based OSI Pharmaceuticals for a price tag of about $3.5 billion. Toyko-based Astellas Pharma today said it...
View Article
